← Russell 3000 cross-section

MLAB MESA LABORATORIES INC /CO/

Trailing twelve months to 2026-06-30 · as filed 2026-08-10, not restated
Industrials

Scale

Market cap
$709m
Revenue TTM
$250m
Net income TTM
$5m
Free cash flow
$53m
Composite score
45.1
Sector rank
#2221

Valuation

P / E
147.7
EV / EBITDA
16.4
EV / sales
3.0
FCF yield
7.46%
Earnings yield vs 10-yr
-4.05pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
1.9%
EBITDA margin
18.2%
ROE
2.5%
ROIC
10.0%
Revenue growth
3.0%

Insider activity, last 90 days

Net open-market
$-0.67m
Buyers
2
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

General Trends Revenue increased 1.0% during the three months ended June 30, 2026 compared to the prior year period, driven by growth in the Calibration Solutions and Biopharmaceutical Development divisions, partially offset by lower revenue in the Sterilization and Disinfection Control division. Revenue in the Clinical Genomics division were essentially flat, as growth outside China offset continued weakness in that market. While revenue in China continued to decrease, the year-over-year reduction was significantly smaller than in the prior-year period following substantial revenue declines in recent fiscal years. …MESA LABORATORIES INC /CO/, 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →